Human placenta-derived mesenchymal stromal cells transfusion in a critically Ill infant diagnosed with Coronavirus Disease 2019 (COVID-19): A case report

Payandeh, Mehrdad; Habibi, Reza; Norooznezhad, Amir Hossein; Hoseinkhani, Zohreh; Mansouri, Feizollah; Yarani, Reza; Thakor, Avnesh S.; Bakhtiari, Mitra; Esmailli, Farzaneh; Mansouri, Kamran

doi:10.1016/j.transci.2022.103454

Cited by 3 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs have been tried as a salvage treatment for critically ill pneumonia patients after the outbreak of the pandemic. In 2020, Chinese physicians successively shared several cases of severe pneumonia treated with MSCs (82-88), and then similar cases began to be reported in other countries and regions (87)(88)(89)(90)(91)(92)(93)(94)(95)(96). The dose range for an intravenous drip of MSCs was (1-3) × 10 6 kg in most of the cases (82)(83)(84)(85)(86)(87)(88)(89)(90)96).…”

Section: Case Reportsmentioning

confidence: 94%

Successful salvage of a severe COVID-19 patient previously with lung cancer and radiation pneumonitis by mesenchymal stem cells: a case report and literature review

Huang,

Tan,

Xie

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

During the COVID-19 pandemic, elderly patients with underlying condition, such as tumors, had poor prognoses after progressing to severe pneumonia and often had poor response to standard treatment. Mesenchymal stem cells (MSCs) may be a promising treatment for patients with severe pneumonia, but MSCs are rarely used for patients with carcinoma. Here, we reported a 67-year-old female patient with lung adenocarcinoma who underwent osimertinib and radiotherapy and suffered from radiation pneumonitis. Unfortunately, she contracted COVID-19 and that rapidly progressed to severe pneumonia. She responded poorly to frontline treatment and was in danger. Subsequently, she received a salvage treatment with four doses of MSCs, and her symptoms surprisingly improved quickly. After a lung CT scan that presented with a significantly improved infection, she was discharged eventually. Her primary disease was stable after 6 months of follow-up, and no tumor recurrence or progression was observed. MSCs may be an effective treatment for hyperactive inflammation due to their ability related to immunomodulation and tissue repair. Our case suggests a potential value of MSCs for severe pneumonia that is unresponsive to conventional therapy after a COVID-19 infection. However, unless the situation is urgent, it needs to be considered with caution for patients with tumors. The safety in tumor patients still needs to be observed.

show abstract

Section: Case Reportsmentioning

confidence: 94%

Successful salvage of a severe COVID-19 patient previously with lung cancer and radiation pneumonitis by mesenchymal stem cells: a case report and literature review

Huang,

Tan,

Xie

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…CD34, 3) differentiate into multiple lineages in vitro , 4) self-renew and exhibit low immunogenicity ( Dominici et al, 2006 ). Over several years, MSCs have gained much attention as a potential therapeutic for several clinical applications such as osteoarthritis, myocardial infarction, graft-versus-host disease (GVHD), diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, kidney injury, amyotrophic lateral sclerosis, spinal cord injury and several other diseases ( Parekkadan and Milwid, 2010 ; Saeedi et al, 2019 ; Payandeh et al, 2022 ; Norooznezhad et al, 2022 ; Ullah et al, 2019 ). In addition, MSCs release soluble factors, extracellular vesicles (EVs) such as exosomes, and microvesicles (MVs) that can collectively act in a paracrine and autocrine fashion to repair tissue and modulate the tissue microenvironment ( Joerger-Messerli et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Umbilical cord mesenchymal stromal cells—from bench to bedside

Chetty

Yarani

Swaminathan

et al. 2022

Front. Cell Dev. Biol.

Self Cite

View full text Add to dashboard Cite

In recent years, mesenchymal stromal cells (MSCs) have generated a lot of attention due to their paracrine and immuno-modulatory properties. mesenchymal stromal cells derived from the umbilical cord (UC) are becoming increasingly recognized as having increased therapeutic potential when compared to mesenchymal stromal cells from other sources. The purpose of this review is to provide an overview of the various compartments of umbilical cord tissue from which mesenchymal stromal cells can be isolated, the differences and similarities with respect to their regenerative and immuno-modulatory properties, as well as the single cell transcriptomic profiles of in vitro expanded and freshly isolated umbilical cord-mesenchymal stromal cells. In addition, we discuss the therapeutic potential and biodistribution of umbilical cord-mesenchymal stromal cells following systemic administration while providing an overview of pre-clinical and clinical trials involving umbilical cord-mesenchymal stromal cells and their associated secretome and extracellular vesicles (EVs). The clinical applications of umbilical cord-mesenchymal stromal cells are also discussed, especially in relation to obstacles and potential solutions for their effective translation from bench to bedside.

show abstract

Multiple drugs

2023

Reactions Weekly

View full text Add to dashboard Cite

Human placenta-derived mesenchymal stromal cells transfusion in a critically Ill infant diagnosed with Coronavirus Disease 2019 (COVID-19): A case report

Cited by 3 publications

References 15 publications

Successful salvage of a severe COVID-19 patient previously with lung cancer and radiation pneumonitis by mesenchymal stem cells: a case report and literature review

Successful salvage of a severe COVID-19 patient previously with lung cancer and radiation pneumonitis by mesenchymal stem cells: a case report and literature review

Umbilical cord mesenchymal stromal cells—from bench to bedside

Multiple drugs

Contact Info

Product

Resources

About